Cygnus Therapeutic Systems announced Monday that theCanadian Health Protection Branch has approved for sale itsNicotrol nicotine transdermal system. The Parke-Davis divisionof Warner-Lambert Canada Inc. and Jouveinal Canada Inc. willsell the prescription product in Canada.
Cygnus (NASDAQ:CYGN) designed, developed and manufacturesNicotrol, which employs a solid state technology to constructthe drug matrix. The Redwood City, Calif., company said thatthis slows the rate of drug delivery, thus minimizing skinirritation.
(c) 1997 American Health Consultants. All rights reserved.